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Candida albicans is a fungus that is an opportunistic pathogen of humans. Normally, C. albicans exists as a harmless commensal
and does not trigger inflammatory responses by resident macrophages in skin mucosa, which may be caused by a tolerance of
skin macrophage to C. albicans. IL-34 is a recently discovered cytokine, constitutively expressed by keratinocytes in the skin. IL-
34 binds to the receptor of M-CSF, thereby stimulating tissue macrophage maturation and differentiation. Resident macrophages
exhibit phenotypic plasticity and may transform into inflammatory M1 macrophages for immunity or anti-inflammatory M2
macrophages for tissue repair. M1 macrophages produce higher levels of inflammatory cytokines such as TNF훼 in response to C.
albicans stimulation. In this study, it was demonstrated that IL-34 attenuated TNF훼 production byM1macrophages challengedwith
heat killed Candida (HKC).The molecular mechanism of IL-34 mediated suppression of HKC induced TNF훼 production by M1
macrophages was by the inhibition of M1macrophage expression of key C. albicans pattern recognition receptors (PPRs), namely,
Toll-like receptor (TLR) 2 and Dectin-1.The results of this study indicated that constitutive IL-34 expressed by skin keratinocytes
might suppress resident macrophage responses to C. albicans colonisation by maintaining low levels TLR2 and Dectin-1 expression
by macrophages.
1. Introduction
Candida albicans is an opportunistic fungal pathogen that
can cause life-threatening infections in severely immuno-
compromised individuals. However, C. albicans is a frequent
coloniser of mucosal surfaces in the majority of healthy
humans without causing disease.This commensal behaviour
has been associated with host immune tolerance [1, 2]. Key
immune surveillance cells in the mucosa that recognise and
respond to C. albicans are resident macrophages, such as
the Langerhans cells of mucosal and dermal skin [3, 4].
Resident macrophages exhibit phenotypic plasticity [5]. M1
macrophages may control Candida infection through phago-
cytosis and also induction of inflammation in the skin by
producing inflammatory cytokines, such as tumour necrosis
factor alpha (TNF훼) [6–8]. M2 macrophages may also kill
Candida by phagocytosis, but, importantly, can also produce
anti-inflammatory cytokines and growth factors leading to
immune tolerance to Candida [1, 9].훽-glucan is a major cell wall component of C. albicans
and binds toToll-like receptor (TLR) 2 andDectin-1 receptors
on M1macrophages to trigger downstream cell signaling for
TNF훼 production [10–12]. We have previously reported the
Granulocyte-Macrophage Colony-Stimulating Factor (GM-
CSF) mediated stimulation of Dectin-1 expression by human
peripheral blood monocytes [13]. This in turn promoted M1
macrophage maturation, Candida phagocytosis, and TNF훼
production [14, 15]. M1 macrophages are normally found at
sites of inflammation of the skin and are associated with
GM-CSF expression by infiltrating and reactive CD4+ T
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cells, resulting in higher levels of TNF훼 [1, 16, 17]. We have
also shown that denture stomatitis involving C. albicans is
associated with higher levels of TNF훼 in fluids from the oral
palatal mucosa [18].
IL-34 is a recently identified cytokine that binds to the
macrophage colonisation factor (M-CSF) receptor (c-fms or
CD115) to stimulate macrophage expansion and maturation.
IL-34 expression occurs predominantly in the skin and brain
where it is produced by keratinocytes and neuronal cells,
respectively [19]. Importantly, mice devoid of IL-34 exhibit
a loss of Langerhans cells in the skin and have a reduced
number of microglia in the brain [20, 21]. The Langerhans
cells and resident macrophages in mucosal and dermal skin
of healthy individuals do not normally respond to C. albicans
or other commensal microorganisms and in these cases there
is no inflammation [22]. Such tolerance could arise through
the presence of locally produced cytokines, such as IL-34.
In the present study, we have examined the potential
role of IL-34 in inducing immune tolerance by resident
macrophages towards heat killed Candida (HKC). This
was undertaken by measuring induced TNF훼 production
and elucidation of molecular mechanisms. The results have
demonstrated, for the first time, that IL-34 acts as an immune
suppressing cytokine which may maintain mucosal and
dermal skin tolerance to C. albicans by downregulating TLR2
and Dectin-1 expression by M1 macrophages, resulting in
lower TNF훼 production.
2. Material and Methods
2.1. Macrophage Culture and Stimulation. Bone marrow
derived macrophages (BMMΦs) were isolated from 6- to
8-week-old C57BL/6 mice as previously described [1] and
cultured with 10 ng/mL GM-CSF (R&D) for 7 days to drive
M1 macrophage maturation. The mouse macrophage cell
line, RAW264.7, was also treated with GM-CSF (10 ng/mL)
for 2 days to induce M1-like macrophages. All cells were
maintained at 37∘C in a 5% (v/v) CO2 enriched atmosphere
in RPMI 1640 medium, supplemented with 10% (v/v) fetal
bovine serum (FBS) containing penicillin and streptomycin.
To investigate TNF훼 production by mouse macrophages,
mature M1 BMMΦs or RAW264.7 cells were first seeded at
levels of 2 × 105 cells in the wells of a 24-well tissue culture
plate. To these cells, IL-34 (R&D Systems) was added at 0, 10,
or 100 ng/mL, and cells were then incubated with the added
presence of 10 ng/mL GM-CSF for 5 (mature M1 BMMΦs)
or 2 (RAW264.7 cells) days. After incubation, 1 × 105 HKC,
which had been prepared as previously described [1, 13], was
added. Wells devoid of HKC served as negative controls. Cell
culture supernatants were collected 24 h after stimulation and
TNF훼was detected using an enzyme-linked immunosorbent
assay (ELISA).
2.2. Detection of Toll-Like Receptor 2 (TLR2) and Dectin-
1 in Mouse Macrophages. To detect TLR2 and Dectin-1
expression by M1 BMMΦs and RAW264.7, cells were treated
with IL-34 at 10 or 100 ng/mL forM1BMMΦs andRAW264.7,
respectively, in the presence of GM-CSF. Cells not exposed
to IL-34 served as controls. M1 BMMΦs were harvested at 0,
24, 48, 72, and 96 h of culture, whilst RAW264.7 cells were
harvested at 6, 12, and 24 h. Total RNA was extracted from
all harvested cells and TLR2 and Dectin-1 expression was
thenmeasured by real-time reverse transcription-polymerase
chain reaction (RT-PCR) and in the case of RAW264.7 cells
also by fluorescence-activated cell sorting (FACS).
2.3. TNF훼 ELISA. TNF훼 in cell culture medium was mea-
sured by ELISA according to the manufacturer’s (eBio-
science) instructions. Briefly, the wells of high protein bound
96-well plates (Nunc) were coated overnight at 4∘C with
50 휇L of anti-mouse TNF훼 specific antibody (0.5 휇g/mL) in
phosphate buffered saline (PBS). After blocking nonspecific
binding using an assay diluent (supplied in the ELISA kit)
for 2 h at room temperature (RT), cell-free supernatants
(50 휇L) and mouse recombinant TNF훼 standards (from
4 ng/mL in two-fold dilutions) were added to the plate
in triplicate prior to overnight incubation at 4∘C to cap-
ture TNF훼. After thoroughly washing the plate with PBS
containing 0.05% (v/v) Tween-20, specific bound TNF훼
was detected using a biotin-conjugated anti-mouse TNF훼
antibody (0.5 휇g/mL) (1 h at RT), followed by incubationwith
50 휇L of StreptAvidin-HRP for 30min at RT. A 50-휇L volume
of 3,3耠,5,5耠-tetramethylbenzidine (TMB) peroxidase substrate
was added to each well and incubated at room temperature
for 10–20min for color development. The enzyme reaction
was terminated by adding 50 휇L of a stop solution (supplied
with the kit). The optical density of each well was then
measured with a spectrometer at 450nm wavelength and the
TNF훼 concentration in the supernatants determined using a
standard curve.
2.4. Real-Time RT-PCR. Total RNA was purified using the
RNeasyMini Kit with QIAshredder spin columns (QIAGEN)
and transcribed into cDNA following the manufacturer’s
recommended protocol using Avian Myeloblastosis Virus
Reverse Transcriptase (AMV RT) (Promega) and 50 ng of
random primers in a total volume of 25휇L for 1 h at 37∘C.The
SYBR green qPCR kit (Sigma) was used to quantify mRNA
levels of TLR2, TLR4, Dectin-1, andMannose Receptor (MR)
using the ABI PRISM 7000 Sequence Detection System
(Applied Biosystems). Table 1 lists the primer pairs that were
used tomeasuremouse receptormRNA levels comparedwith
the mouse housekeeping 훽-actin gene (Table 1).
All samples were run in triplicate. The cycle threshold
(CT) value of each sample was determined by calculation of
2−ΔΔCT, and the data was presented as an expression-fold
relative to control.
2.5. FACS Analysis. RAW264.7 cells, with or without IL-34
treatment, were harvested at specific time points and fixed
in 300 휇L of FACS buffer containing 2% (v/v) paraformalde-
hyde for 30min at 4∘C. After blocking nonspecific binding
with 5% (v/v) rabbit serum for 20min at 4∘C, cells were
incubated either with FITC-conjugated anti-TLR2 antibody
(eBioscience), Phycoerythrin- (PE-) conjugated anti-Dectin-
1 antibody (eBioscience), or isotype control antibodies
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Figure 1: IL-34 suppressed HKC induced TNF훼 production in M1 macrophages. (a) IL-34 dose dependent suppression of HKC induced
TNF훼 production in mouse bone marrow derived M1 macrophages. The differences of induced TNF훼 production between 10 ng/mL and
100 ng/mL of IL-34 were also significant (푃 < 0.05). (b) IL-34 suppression of HKC induced TNF훼 production in M1 macrophage like cell
line, derived from RAW264.7 cells. ∗푃 < 0.05 and ∗∗푃 < 0.01.
Table 1: Primers used for real-time RT-PCR analysis of mouse
receptor mRNA.
mDectin-1-P1 TGGTAGTAGTGGTTGCTGCAGTGCTGGG
mDectin-1-P2 GTAGTTTGGGATGCCTTGGAGGGAGCCA
mMR-P1 GGTACACTAACTGGGGTGCTGACGAGCC
mMR-P2 ACTCTGGACACTTGCCAGGCAGTTGAGG
mTLR4-P1 GGCACTGTTCTTCTCCTGCCTGACACCA
mTLR4-P2 AGGGACTTTGCTGAGTTTCTGATCCATGC
mTLR2-P1 GGAGCATCCGAATTGCATCACCGGTCAGA
mTLR2-P2 GGCCATCACACACCCCAGAAGCATCACA
M훽-actin-P1 CTTCTTTGCAGCTCCTTCGTTGCCGGT
M훽-actin-P2 CCTTCTGACCCATTCCCACCATCACACC
diluted in FACS buffer for 30min at 4∘C. Samples were
analysed by collecting 10,000 events using the FACSCanto II
flow cytometer (BD Biosciences). The change in percentage
of both TLR2 and Dectin-1 positive cells after treatment with
IL-34 was determined and compared to cells without IL-34
treatment.
2.6. Statistical Analysis. Results were calculated as means ±
standard deviations (SD). Statistical significance was deter-
mined using two-tailed Student’s 푡-test and Tukey-Kramer
or Bonferroni multiple comparisons post-tests to analyse
differences between groups; ∗푃 < 0.05 and ∗∗푃 < 0.01 were
considered significant.
3. Results
3.1. IL-34 Suppressed HKC Induced TNF훼 Production in M1
Macrophages in a Dose Dependent Manner. HKC stimulated
TNF훼 production by M1 macrophages, which is one of the
phenotypic features of M1 macrophages [1]. To assess the
effect of IL-34 on the inflammatory M1 macrophage, M1
macrophageswere pretreatedwith different concentrations of
IL-34 for 5 days in the presence of GM-CSF, prior to the cells
being stimulated with HKC. Decreased TNF훼 production
in culture supernatant was determined by ELISA in a HKC
dose dependent manner (Figure 1(a)). These results were
confirmed using the cultured mouse macrophage cell line
(RAW264.7). However, treatment of RAW264.7 cells with
GM-CSF for two days, followed by 2 days treatment with IL-
34, demonstrated suppression towards HKC induced TNF훼
production in an IL-34 dose dependentmanner (Figure 1(b)).
This result showed that IL-34 was acting as an immune sup-
pressing cytokine that was able to inhibit TNF훼 production
by inflammatory M1 macrophages in response to Candida
stimulation.
3.2. IL-34 Inhibited TLR2 and Dectin-1 mRNA Expression by
M1Macrophages. The recognition of Candida cell wall com-
ponents by macrophages involves Toll-like receptors (TLRs,
mainly TLR2 and TLR4) andC-type lectin receptors (Dectin-
1 and Mannose Receptor). To investigate the molecular
mechanism of IL-34 suppression of Candida induced TNF훼
production by M1macrophages, the mRNAs of TLR2, TLR4,
Dectin-1, andMannose Receptor were measured by RT-PCR.
IL-34 treated cells expressed significantly lower mRNA for
TLR2 and Dectin-1 (푃 < 0.01) (Figure 2(a)). There was,
however, no significant decrease in the expression of mRNA
for TLR4 (Figure 2(b)). Interestingly, Mannose Receptor
was significantly upregulated by IL-34 in M1 macrophages
(Figure 2(b)). IL-34 suppression of TLR2 andDectin-1mRNA
was confirmed using RAW264.7 cells (Figure 2(c)). These
results showed that IL-34 suppression of HKC stimulated
TNF훼 production was via the downregulation of TLR2 and
Dectin-1 expression by M1 macrophages and not by the
downregulation of TLR4 or Mannose Receptor.
4 Journal of Immunology Research
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Figure 2: IL-34 suppressed TLR2 and Dectin-1mRNA expression in M1macrophages. M1macrophages derived from mouse bone marrow
cells were cultured with or without mouse recombinant IL-34 (100 ng/mL). (a)The mRNA expression of TLR2 and Dectin-1 was decreased.
(b) TLR4 expressionwas not altered by IL-34. However,Mannose Receptor (MR)was significantly upregulated by IL-34. (c) IL-34 suppressing
TLR2 and Dectin-1 was confirmed in RAW264.7 cell lines in a dose dependent manner.The results are the representative of 3 experiments.∗푃 < 0.05 and ∗∗푃 < 0.01.
3.3. Detection of Reduced TLR2 and Dectin-1 Cell Surface
Expression in M1 Macrophages. TLR2 and Dectin-1 cell
surface expression can be detected by FACS analysis using
anti-TLR2 and anti-Dectin-1 receptor specific antibodies. To
confirm downregulation of cell surface TLR2 and Dectin-1
following IL-34 stimulation, M1 macrophages treated with
different concentrations of IL-34 were stained with FITC-
conjugated anti-TLR2 and PE-conjugated anti-Dectin-1. A
dose dependent decrease in TLR2 (Figure 3(a)) and Dectin-
1 (Figure 3(b)) positive cell populations of M1 macrophages
was demonstrated by FACS analysis. These results further
demonstrated that IL-34 treatment of M1 macrophage cell
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Figure 3: IL-34 suppressed cell surface expression of TLR2 and Dectin-1 in bonemarrow derivedM1macrophages. Cell surface expression of
TLR2 andDectin-1 decreasedwith increasing IL-34 levels in cultures.The bar figures showed percentage changes with positive cell staining for
TLR2 and Dectin-1, respectively. Isotype staining was used as negative controls.The results are representative of 3 independent experiments.
cultures reduced cell surface expression of TLR2 and Dectin-
1, resulting in inhibition of Candida induced TNF훼 produc-
tion by M1macrophages.
4. Discussion
Mucosal and dermal skin provides a physical and biolog-
ical barrier against insult from both the environment and
pathogens. These surfaces also exhibit tolerance to com-
mensal microorganisms such as C. albicans that colonise
them. This immune tolerance arises as a result of a complex
interaction of cell components including tissue resident
macrophages such as Langerhans cells in the epidermal
layers of skin [22, 23]. Tissue resident macrophages exhibit
phenotypic plasticity. GM-CSF induces an inflammatory
M1 macrophage phenotype in vitro and in vivo, and M1
macrophages produce TNF훼 in response to C. albicans
stimulation [6–8].
In this study, we demonstrated that IL-34, a cytokine
constitutively produced in the skin, was able to suppress
inflammatory M1 macrophages for HKC induced TNF훼
production. This suppressing activity was demonstrated for
M1macrophages cultured in the presence of GM-CSF, which
indicated that IL-34 was an antagonist of GM-CSF. Recent
6 Journal of Immunology Research
studies have shown that Langerhans cells exhibit immune
tolerance and do not normally induce an immune response
even after activation andmigration to a draining lymph node
[22]. This immune tolerance may be the result of an IL-34
rich environment in the skin. The evidence for the immune
tolerant phenotype of Langerhans cells and IL-34 inducing
non-TNF훼 producing macrophages suggests that IL-34 is an
immune suppressing cytokine of the skin. However, studies
of autoimmune rheumatoid arthritis have indicated that
IL-34 may be a proinflammatory cytokine with expression
associated with joint inflammation [24–28]. IL-34 shares
the receptor for M-CSF, which is a key factor in inducing
osteoclast formation. Indeed, it has been demonstrated that
IL-34 has involvement in cartilage and bone erosion by
promoting osteoclastogenesis in rheumatoid arthritis [25,
26]. Although it has been shown that increasing IL-34
levels is associated with synovitis severity of rheumatoid
arthritis patients [24], IL-34 expression could suppress joint
inflammation as a negative feedback instead of promoting
inflammation. Studies have also shown that suppressing
M1 macrophages reduces collagen induced arthritis in mice
[29]. It has been demonstrated that CD14+ macrophages in
synovial tissue are a major source of TNF훼 [30]. The role of
IL-34 in joint inflammation may need to be analysed with
greater focus given to the impact of this cytokine on M1
macrophages in synovial tissues of patients.
TNF훼 is a key proinflammatory cytokine in both skin
and joint inflammation. We have recently demonstrated that
higher TNF훼 production and inflammation in oral mucosa
was associatedwithC. albicans infection in denture stomatitis
[18]. Following sufficient control of C. albicans colonisation
in such patients, a reduction ofM1macrophage activity using
IL-34might therefore be beneficial.
Candida albicans stimulation of macrophages leading
to TNF훼 production requires expression of the pattern
recognition receptors, TLR2 and Dectin-1 [10–12, 31]. In the
current study, we have shown for the first time that IL-
34 can suppress both TLR2 and Dectin-1 mRNA transcrip-
tion, but not transcription of TLR4 and Mannose Receptor.
Both cell surface TLR2 and Dectin-1 expression was also
suppressed by IL-34 in a dose dependent manner. These
findings indicate that TLR2 and Dectin-1 (but not TLR4 and
Mannose Receptor) are the cell surface receptors responsible
for TNF훼 production by M1 macrophages. IL-34 expression
is restricted to the epidermal layers of skin and certain
areas of the brain [19]. Regeneration of Langerhans cells
in mucosal and dermal skin is entirely dependent on IL-
34 production in keratinocytes. Loss of Langerhans cells
occurs in IL-34 deficient mice indicating that the function
of IL-34 cannot be undertaken by M-CSF, despite IL-34 and
M-CSF sharing a common receptor (c-fms or CD115) in
macrophage precursor cells. The results of the present study
provide evidence that constitutive expression of IL-34 in the
skin may maintain an environment of immune tolerance for
tissue resident macrophages. In this study, IL-34 stimulated a
significantly higher Mannose Receptor (CD206) expression,
which is a cell marker for M2 macrophages and responsible
for phagocytosis.This result further demonstrated that IL-34
was able to promote M1 to M2 macrophage transformation,
which could be of benefit in generating immune tolerance
and wound healing in the skin.
In conclusion, this study demonstrated that IL-34 sup-
presses C. albicans induced TNF훼 production by GM-CSF
induced M1 macrophages. The mechanism of inhibition
was through the downregulation of TLR2 and Dectin-1
expression by M1 macrophages, but not TLR4 and Mannose
Receptor. Constitutive IL-34 expression in keratinocytes in
both mucosal skin and dermal skin may play a key role in
maintaining immune tolerance toward commensal colonis-
ing microorganisms.
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